Antibody mimetic binders targeting either ERK1/2 or the phosphorylated ERK1/2 were developed (Figure 4A), but their potency to inhibit cell proliferation in vitro and tumour growth in vivo needs to be assessed [137]. Here, MAPK3 is linked to neoplasm.